Skip to main content

Advertisement

SpringerLink
Log in

Nobiletin as a Molecule for Formulation Development: An Overview of Advanced Formulation and Nanotechnology-Based Strategies of Nobiletin

  • Review Article
  • Theme: Formulation and Delivery of Natural Products
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

Approximately 40% of compounds in clinical drug development suffer from solubility and bioavailability challenges. Evidence from literature demonstrates the growing interest to utilize flavonoids as potential compounds owing to their widespread therapeutic utility in various ailments. Nobiletin (NOB), one such dietary polymethoxylated flavonoid found in citrus fruits, has multiple pharmacological effects such as antioxidant, anti-microbial, anti-cancer, and anti-inflammatory. It is useful in cancer, inflammatory bowel diseases, atherosclerosis, obesity, and Alzheimer’s disease. Although preclinical studies demonstrate the therapeutic utility of NOB, it suffers from serious biopharmaceutical limitations such as low aqueous solubility (below 1 μg/ml), poor permeability across biological barriers, and low bioavailability. To overcome these biopharmaceutical challenges associated with NOB, the use of advanced formulations and nanotechnology-based strategies appears to be a promising approach to potentiate its therapeutic action. Multiple reviews cover the various therapeutic benefits of NOB in various diseases; however, there is an absence of a comprehensive review that focuses on the formulation development strategies of NOB. The purpose of this review is to provide a concise perspective on NOB as a candidate molecule for formulation development. The manuscript covers various aspects related to NOB, such as its chemistry, physicochemical properties, and pharmacological effects. This is also a thorough review of various formulation development strategies with advances made in the past years to improve the solubility, bioavailability, and therapeutic efficacy of NOB. The review also contains information related to toxicity and patents involving NOB and its formulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Hattori T, Tagawa H, Inai M, Kan T, Kimura S, Itai S, et al. Transdermal delivery of nobiletin using ionic liquids. Sci Rep. 2019;9(1):1–11.

    Google Scholar 

  2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1–3):3–25.

    CAS  Google Scholar 

  3. Julio A, Lima SAC, Reis S, de Almeida TS, Fonte P. Development of ionic liquid-polymer nanoparticle hybrid systems for delivery of poorly soluble drugs. J Drug Deliv Sci Technol. 2019;100915.

  4. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.

    CAS  PubMed  Google Scholar 

  5. Ghadi R, Dand N. BCS class IV drugs: highly notorious candidates for formulation development. J Control Release. 2017;248:71–95.

    CAS  PubMed  Google Scholar 

  6. Dressman J, Butler J, Hempenstall J, Reppas C. The BCS: where do we go from here? Pharm Technol. 2001;25(7):68–77.

    CAS  Google Scholar 

  7. Di AC, Angelico R. Advanced nanotechnologies for enhancing the bioavailability of silymarin: a state of the art. 2019.

    Google Scholar 

  8. Kumar S, Kesharwani SS, Mathur H, Tyagi M, Bhat GJ, Tummala H. Molecular complexation of curcumin with pH sensitive cationic copolymer enhances the aqueous solubility, stability and bioavailability of curcumin. Eur J Pharm Sci. 2016;82:86–96.

    CAS  PubMed  Google Scholar 

  9. Kesharwani SS, Ahmad R, Bakkari MA, Rajput MK, Dachineni R, Valiveti CK, et al. Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD): formulation development, characterization and pharmacological evaluation. J Control Release. 2018;290:165–79.

    CAS  PubMed  Google Scholar 

  10. Tang C, Hoo PC-X, Tan LT-H, Pusparajah P, Khan TM, Lee L-H, et al. Golden needle mushroom: a culinary medicine with evidenced-based biological activities and health promoting properties. Front Pharmacol. 2016;7:474.

    PubMed  PubMed Central  Google Scholar 

  11. Alam MN, Almoyad M, Huq F. Polyphenols in colorectal cancer: current state of knowledge including clinical trials and molecular mechanism of action. Biomed Res Int. 2018;2018:1–29.

    Google Scholar 

  12. Sankaranarayanan R, Valiveti CK, Kumar DR, Kesharwani SS, Seefeldt T, Scaria J, et al. The flavonoid metabolite 2, 4, 6-trihydroxybenzoic acid is a CDK inhibitor and an anti-proliferative agent: a potential role in cancer prevention. Cancers. 2019;11(3):427.

    CAS  PubMed Central  Google Scholar 

  13. Dachineni R, Kumar DR, Callegari E, Kesharwani SS, Sankaranarayanan R, Seefeldt T, et al. Salicylic acid metabolites and derivatives inhibit CDK activity: novel insights into aspirin's chemopreventive effects against colorectal cancer. Int J Oncol. 2017;51(6):1661–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Thilakarathna SH, Rupasinghe H. Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients. 2013;5(9):3367–87.

    PubMed  PubMed Central  Google Scholar 

  15. Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005;81(1):230S–42S.

    CAS  PubMed  Google Scholar 

  16. Li J, Yang Y, Ning E, Peng Y, Zhang J. Mechanisms of poor oral bioavailability of flavonoid Morin in rats: from physicochemical to biopharmaceutical evaluations. Eur J Pharm Sci. 2019;128:290–8.

    CAS  PubMed  Google Scholar 

  17. Di Costanzo A, Angelico R. Formulation strategies for enhancing the bioavailability of silymarin: the state of the art. Molecules. 2019;24(11):2155.

    PubMed Central  Google Scholar 

  18. Goh JXH, Tan LT-H, Goh JK, Chan KG, Pusparajah P, Lee LH, et al. Nobiletin and derivatives: functional compounds from citrus fruit peel for colon cancer chemoprevention. Cancers. 2019;11(6):867.

    CAS  PubMed Central  Google Scholar 

  19. Huang H, Li L, Shi W, Liu H, Yang J, Yuan X, et al. The multifunctional effects of nobiletin and its metabolites in vivo and in vitro. Evid Based Complement Alternat Med. 2016;2016:1–14.

    CAS  Google Scholar 

  20. Moon JY, Cho M, Ahn KS, Cho SK. Nobiletin induces apoptosis and potentiates the effects of the anticancer drug 5-fluorouracil in p53-mutated SNU-16 human gastric cancer cells. Nutr Cancer. 2013;65(2):286–95.

    CAS  PubMed  Google Scholar 

  21. Chen C, Ono M, Takeshima M, Nakano S. Antiproliferative and apoptosis-inducing activity of nobiletin against three subtypes of human breast cancer cell lines. Anticancer Res. 2014;34(4):1785–92.

    CAS  PubMed  Google Scholar 

  22. Abe S, Hirose S, Nishitani M, Yoshida I, Tsukayama M, Tsuji A, et al. Citrus peel polymethoxyflavones, sudachitin and nobiletin, induce distinct cellular responses in human keratinocyte HaCaT cells. Biosci Biotechnol Biochem. 2018;82(12):2064–71.

    CAS  PubMed  Google Scholar 

  23. Borah N, Gunawardana S, Torres H, McDonnell S, Van Slambrouck S. 5,6,7,3′,4′,5'-Hexamethoxyflavone inhibits growth of triple-negative breast cancer cells via suppression of MAPK and Akt signaling pathways and arresting cell cycle. Int J Oncol. 2017;51(6):1685–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Chiou Y-S, Zheng Y-N, Tsai M-L, Lai C-S, Ho C-T, Pan M-H. 5-Demethylnobiletin more potently inhibits colon cancer cell growth than nobiletin in vitro and in vivo. J Food Bioact. 2018;2:91–7.

    Google Scholar 

  25. Du Q, Chen H. The methoxyflavones in Citrus reticulata Blanco cv. ponkan and their antiproliferative activity against cancer cells. Food Chem. 2010;119(2):567–72.

    CAS  Google Scholar 

  26. Kunimasa K, Ikekita M, Sato M, Ohta T, Yamori Y, Ikeda M, et al. Nobiletin, a citrus polymethoxyflavonoid, suppresses multiple angiogenesis-related endothelial cell functions and angiogenesis in vivo. Cancer Sci. 2010;101(11):2462–9.

    CAS  PubMed  Google Scholar 

  27. Miyamoto S, Yasui Y, Tanaka T, Ohigashi H, Murakami A. Suppressive effects of nobiletin on hyperleptinemia and colitis-related colon carcinogenesis in male ICR mice. Carcinogenesis. 2008;29(5):1057–63.

    CAS  PubMed  Google Scholar 

  28. Sousa DP, Pojo M, Pinto AT, Leite V, Serra AT, Cavaco BM. Nobiletin alone or in combination with cisplatin decreases the viability of anaplastic thyroid cancer cell lines. Nutr Cancer. 2020;72(2):352–63.

    CAS  PubMed  Google Scholar 

  29. Tung Y-C, Chou Y-C, Hung W-L, Cheng A-C, Yu R-C, Ho C-T, et al. Polymethoxyflavones: chemistry and molecular mechanisms for cancer prevention and treatment. Curr Pharmacol Rep. 2019;5(2):98–113.

    CAS  Google Scholar 

  30. Wang Y, Xie J, Ai Z, Su J. Nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis. Int J Nanomedicine. 2019;14:7839–49.

    PubMed  PubMed Central  Google Scholar 

  31. Yao X, Zhu X, Pan S, Fang Y, Jiang F, Phillips GO, et al. Antimicrobial activity of nobiletin and tangeretin against pseudomonas. Food Chem. 2012;132(4):1883–90.

    CAS  Google Scholar 

  32. Li S, Sang S, Pan M-H, Lai C-S, Lo C-Y, Yang CS, et al. Anti-inflammatory property of the urinary metabolites of nobiletin in mouse. Bioorg Med Chem Lett. 2007;17(18):5177–81.

    CAS  PubMed  Google Scholar 

  33. Liao W, Liu Z, Zhang T, Sun S, Ye J, Li Z, et al. Enhancement of anti-inflammatory properties of nobiletin in macrophages by a nano-emulsion preparation. J Agric Food Chem. 2018;66(1):91–8.

    CAS  PubMed  Google Scholar 

  34. Lin N, Sato T, Takayama Y, Mimaki Y, Sashida Y, Yano M, et al. Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem Pharmacol. 2003;65(12):2065–71.

    CAS  PubMed  Google Scholar 

  35. Manthey JA, Bendele P. Anti-inflammatory activity of an orange peel polymethoxylated flavone, 3′, 4′, 3, 5, 6, 7, 8-heptamethoxyflavone, in the rat carrageenan/paw edema and mouse lipopolysaccharide-challenge assays. J Agric Food Chem. 2008;56(20):9399–403.

    CAS  PubMed  Google Scholar 

  36. Wu X, Mei Z, Zheng D, Liu Z, Zhu X, Zhou Y, et al. Application of nobiletin in preparation or screening of diabetic cardiomyopathy. Drug. 2018.

  37. Nakajima A, Aoyama Y, Shin E-J, Nam Y, Kim H-C, Nagai T, et al. Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble Aβ levels in a triple transgenic mouse model of Alzheimer’s disease (3XTg-AD). Behav Brain Res. 2015;289:69–77.

    CAS  PubMed  Google Scholar 

  38. Seki T, Kamiya T, Furukawa K, Azumi M, Ishizuka S, Takayama S, et al. Nobiletin-rich Citrus reticulata peels, a kampo medicine for Alzheimer’s disease: a case series. Geriatr Gerontol Int. 2013;13(1):236–8.

    PubMed  Google Scholar 

  39. Hu Y, Shu Q, Liu F, Lei L, Li B, Cao Y, et al. Ca2+−induced whey protein emulgels for the encapsulation of crystalline nobiletin: effect of nobiletin crystals on the viscoelasticity. Food Hydrocoll. 2019;94:57–62.

    CAS  Google Scholar 

  40. Tsukayama M, Ichikawa R, Yamamoto K, Sasaki T, Kawamura Y. Microwave-assisted rapid extraction of polymethoxyflavones from dried peels of Citrus yuko Hort. ex Tanaka. Nippon Shokuhin Kagaku Kogaku Kaishi J Jpn Soc Food Sci Technol. 2009;56(6):359–62.

    CAS  Google Scholar 

  41. Chen S, Cai D, Pearce K, Sun PY, Roberts AC, Glanzman DL. Reinstatement of long-term memory following erasure of its behavioral and synaptic expression in Aplysia. Elife. 2014;3:e03896.

    PubMed  PubMed Central  Google Scholar 

  42. Zheng J, Bi J, Johnson D, Sun Y, Song M, Qiu P, et al. Analysis of 10 metabolites of polymethoxyflavones with high sensitivity by electrochemical detection in high-performance liquid chromatography. J Agric Food Chem. 2015;63(2):509–16.

    CAS  PubMed  Google Scholar 

  43. Zheng J, Song M, Dong P, Qiu P, Guo S, Zhong Z, et al. Identification of novel bioactive metabolites of 5-demethylnobiletin in mice. Mol Nutr Food Res. 2013;57(11):1999–2007.

    CAS  PubMed  Google Scholar 

  44. Koga N, Ohta C, Kato Y, Haraguchi K, Endo T, Ogawa K, et al. In vitro metabolism of nobiletin, a polymethoxy-flavonoid, by human liver microsomes and cytochrome P450. Xenobiotica. 2011;41(11):927–33.

    CAS  PubMed  Google Scholar 

  45. Li S, Wang Z, Sang S, Huang MT, Ho CT. Identification of nobiletin metabolites in mouse urine. Mol Nutr Food Res. 2006;50(3):291–9.

    CAS  PubMed  Google Scholar 

  46. Wang M. Biotransformation of polymethoxyflavones and its implication on biological activities. 2017.

    Google Scholar 

  47. Xu L, He Y, Guo X, Lu Y, Wang C, Wang Z. Identification of metabolites of nobiletin in rats using ultra-performance liquid chromatography coupled with triple-quadrupole mass spectrometry. Yao xue xue bao Acta Pharm Sin. 2011;46(12):1483–7.

    CAS  Google Scholar 

  48. Wu X, Song M, Wang M, Zheng J, Gao Z, Xu F, et al. Chemopreventive effects of nobiletin and its colonic metabolites on colon carcinogenesis. Mol Nutr Food Res. 2015;59(12):2383–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Xiong Y, Chen D, Yu C, Lv B, Peng J, Wang J, et al. Citrus nobiletin ameliorates experimental colitis by reducing inflammation and restoring impaired intestinal barrier function. Mol Nutr Food Res. 2015;59(5):829–42.

    CAS  PubMed  Google Scholar 

  50. Nagase H, Omae N, Omori A, Nakagawasai O, Tadano T, Yokosuka A, et al. Nobiletin and its related flavonoids with CRE-dependent transcription-stimulating and neuritegenic activities. Biochem Biophys Res Commun. 2005;337(4):1330–6.

    CAS  PubMed  Google Scholar 

  51. Matsuzaki K, Yamakuni T, Hashimoto M, Haque AM, Shido O, Mimaki Y, et al. Nobiletin restoring β-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer’s disease model rats. Neurosci Lett. 2006;400(3):230–4.

    CAS  PubMed  Google Scholar 

  52. Gao Z, Gao W, Zeng S-L, Li P, Liu E-H. Chemical structures, bioactivities and molecular mechanisms of citrus polymethoxyflavones. J Funct Foods. 2018;40:498–509.

    CAS  Google Scholar 

  53. Lin SC, Chen MC, Li S, Lin CC, Wang TT. Antiviral activity of nobiletin against chikungunya virus in vitro. Antivir Ther. 2017;22(8):689–97.

    CAS  PubMed  Google Scholar 

  54. Rooprai HK, Kandanearatchi A, Maidment S, Christidou M, Trillo-Pazos G, Dexter DT, et al. Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro. Neuropathol Appl Neurobiol. 2001;27(1):29–39.

    CAS  PubMed  Google Scholar 

  55. Kim H, Moon JY, Mosaddik A, Cho SK. Induction of apoptosis in human cervical carcinoma HeLa cells by polymethoxylated flavone-rich Citrus grandis Osbeck (Dangyuja) leaf extract. Food Chem Toxicol. 2010;48(8–9):2435–42.

    CAS  PubMed  Google Scholar 

  56. Li S, Pan M-H, Lo C-Y, Tan D, Wang Y, Shahidi F, et al. Chemistry and health effects of polymethoxyflavones and hydroxylated polymethoxyflavones. J Funct Foods. 2009;1(1):2–12.

    CAS  Google Scholar 

  57. Luque-Alcaraz AG, Lizardi J, Goycoolea FM, Valdez MA, Acosta AL, Iloki-Assanga SB, et al. Characterization and antiproliferative activity of nobiletin-loaded chitosan nanoparticles. J Nanomater. 2012;2012:1–7.

    Google Scholar 

  58. Huang Y, Wu D, Bao M, Li B, Liang H. Coordination driven self-assembly for enhancing the biological stability of nobiletin. J Mol Liq. 2019;292:111420.

    CAS  Google Scholar 

  59. Yao J, Lu Y, Zhou JP. Preparation of nobiletin in self-microemulsifying systems and its intestinal permeability in rats. J Pharm Pharm Sci. 2008;11(3):22–9.

    CAS  PubMed  Google Scholar 

  60. Sun G, Lei L, Chen H, Li B, Cao Y, Li Y. Tailoring of structured hydroxypropyl methylcellulose-stabilized emulsions for encapsulation of nobiletin: modification of the oil and aqueous phases. Food Funct. 2018;9(7):3657–64.

    CAS  PubMed  Google Scholar 

  61. Yao J, Zhou JP, Ping QN, Lu Y, Chen L. Distribution of nobiletin chitosan-based microemulsions in brain following iv injection in mice. Int J Pharm. 2008;352(1–2):256–62.

    CAS  PubMed  Google Scholar 

  62. Onoue S, Uchida A, Takahashi H, Seto Y, Kawabata Y, Ogawa K, et al. Development of high-energy amorphous solid dispersion of nanosized nobiletin, a citrus polymethoxylated flavone, with improved oral bioavailability. J Pharm Sci. 2011;100(9):3793–801.

    CAS  PubMed  Google Scholar 

  63. Huang W, Dou H, Wu H, Sun Z, Wang H, Huang L. Preparation and characterisation of nobiletin-loaded nanostructured lipid carriers. J Nanomater. 2017;2017:1–10.

    Google Scholar 

  64. Jeong HJ, Nam SJ, Song JY, Park SN. Synthesis and physicochemical properties of pH-sensitive hydrogel based on carboxymethyl chitosan/2-hydroxyethyl acrylate for transdermal delivery of nobiletin. J Drug Deliv Sci Technol. 2019;51:194–203.

    CAS  Google Scholar 

  65. Wu D, Liang Y, Pei Y, Li B, Liang H. Plant exine capsules based encapsulation strategy: a high loading and long-term effective delivery system for nobiletin. Food Res Int. 2020;127:108691.

    CAS  PubMed  Google Scholar 

  66. Lei L, Zhang Y, He L, Wu S, Li B, Li Y. Fabrication of nanoemulsion-filled alginate hydrogel to control the digestion behavior of hydrophobic nobiletin. LWT-Food Sci Technol. 2017;82:260–7.

    CAS  Google Scholar 

  67. Kumar CS. Biological and pharmaceutical nanomaterials. Biological and Pharmaceutical Nanomaterials, by Challa SSR Kumar (Editor), pp 425 ISBN 3–527–31382-6 Wiley-VCH, 2006 425.

  68. Baghel S, Cathcart H, O'Reilly NJ. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 2016;105(9):2527–44.

    CAS  PubMed  Google Scholar 

  69. He Y, Ho C. Amorphous solid dispersions: utilization and challenges in drug discovery and development. J Pharm Sci. 2015;104(10):3237–58.

    CAS  PubMed  Google Scholar 

  70. Iwashita M, Hashizume K, Umehara M, Ishigami T, Onishi S, Yamamoto M, et al. Development of nobiletin–methyl hesperidin amorphous solid dispersion: novel application of methyl hesperidin as an excipient for hot-melt extrusion. Int J Pharm. 2019;558:215–24.

    CAS  PubMed  Google Scholar 

  71. Iwashita M, Umehara M, Onishi S, Yamamoto M, Yamagami K, Ishigami T. Method for producing nobiletin-containing solid dispersion2019 20 June 2019.

  72. Wani RJ, Sharma P, Zhong HA, Chauhan H. Preparation and characterization of griseofulvin solid dispersions. ASSAY Drug Dev Technol. 2020;18(3):109–18.

    CAS  PubMed  Google Scholar 

  73. Hu T, Jiang J-G. Application of nanotechnology in traditional Chinese medicine. Curr Nanosci. 2012;8(3):474–84.

    CAS  Google Scholar 

  74. Meng F, Trivino A, Prasad D, Chauhan H. Investigation and correlation of drug polymer miscibility and molecular interactions by various approaches for the preparation of amorphous solid dispersions. Eur J Pharm Sci. 2015;71:12–24.

    CAS  PubMed  Google Scholar 

  75. Jordan S, Murty M, Pilon K. Products containing bitter orange or synephrine: suspected cardiovascular adverse reactions. Can Med Assoc J. 2004;171(8):993–4.

    Google Scholar 

  76. Delaney B, Phillips K, Vasquez C, Wilson A, Cox D, Wang HB, et al. Genetic toxicity of a standardized mixture of citrus polymethoxylated flavones. Food Chem Toxicol. 2002;40(5):617–24.

    CAS  PubMed  Google Scholar 

  77. Qu Y, Liu Y, Chen L, Zhu Y, Xiao X, Wang D, et al. Nobiletin prevents cadmium-induced neuronal apoptosis by inhibiting reactive oxygen species and modulating JNK/ERK1/2 and Akt/mTOR networks in rats. Neurol Res. 2018;40(3):211–20.

    CAS  PubMed  Google Scholar 

  78. Yang G, Li S, Long T, Yang Y, Li Y, inventors. Application of polymethoxyflavone in preparation of prevention drug for cardiovascular inflammation 2017 24 October 2017.

  79. Wu X, Zheng D, Qin Y, Lui Z, Zhu X, inventors. Application of nobiletin in medicine for preventing or treating heart failure.2017 7 July 2017.

  80. Morimoto T, Hasegawa K, Murakami A, Fukuda H, Takahashi K, inventors. Cardiac disease treatment agents containing nobiletin.2011 24 February 2011.

  81. Guthrie N, inventor.Compositions comprising at least one polymethoxyflavone, flavonoid, liminoid, and/or tocotrienol useful in combination therapies for treating diabetes.2014 24 December 2014.

  82. Caramelli G, inventor. Product with blood lipid-loweing activity.2008 2 August 2008.

  83. Zhang T, Liao M, Gong S, Xie X, Sun W, Wang L, et al., inventorsApplication of total flavonoid extract from Citrus aurantium in manufacturing medicines for treating asthma. 2013 20 February 2013.

Download references

Acknowledgments

Siddharth S. Kesharwani and Surajit Dey would like to acknowledge the College of Pharmacy, Roseman University of Health Sciences, USA.

Author information

Authors and Affiliations

  1. College of Pharmacy, Roseman University of Health Sciences, 10920 S. River Front Parkway, South Jordan, Utah, 84095, USA

    Siddharth S. Kesharwani

  2. Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, 570015, India

    Pooja Mallya, Vadikari Arun Kumar & Vikas Jain

  3. Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Nebraska, 68198, Omaha, USA

    Swagat Sharma

  4. College of Pharmacy, Roseman University of Health Sciences, 11 Sunset Way, Henderson, 89014, Nevada, USA

    Surajit Dey

Authors
  1. Siddharth S. Kesharwani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pooja Mallya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vadikari Arun Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vikas Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Swagat Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Surajit Dey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siddharth S. Kesharwani.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Guest Editors: Harsh Chauhan, Abhijit Date and Sonali Dhindwal

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kesharwani, S.S., Mallya, P., Kumar, V.A. et al. Nobiletin as a Molecule for Formulation Development: An Overview of Advanced Formulation and Nanotechnology-Based Strategies of Nobiletin. AAPS PharmSciTech 21, 226 (2020). https://doi.org/10.1208/s12249-020-01767-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12249-020-01767-0

KEY WORDS

Search

Navigation